Buyers will give attention to updates on lead pipeline candidate silevertinib when Black Diamond Therapeutics BDTX reviews third-quarter outcomes shortly. The Zacks Consensus Estimate for loss per share is pegged at 22 cents.
Earnings estimate for 2025 has decreased a penny to 35 cents per share whereas loss per share for 2026 has widened to 89 cents from 82 cents.
Picture Supply: Zacks Funding Analysis
BDTX’s Earnings Shock Historical past
BDTX has a superb observe file. Its earnings beat estimates in every of the trailing 4 quarters, delivering a mean shock of 1,214%. Within the final reported quarter, the corporate’s earnings beat estimates by 24%.
Picture Supply: Zacks Funding Analysis
What Our Mannequin Predicts for BDTX
Per our confirmed mannequin, the mix of a optimistic Earnings ESP and a Zacks Rank #1 (Sturdy Purchase), 2 (Purchase) or 3 (Maintain) will increase the percentages of an earnings beat.
Earnings ESP for BDTX is -2.68%. The corporate at the moment carries a Zacks Rank #3. You’ll be able to uncover the perfect shares to purchase or promote earlier than they’re reported with our Earnings ESP Filter.
Components Influencing BDTX’s Q3 Outcomes
Since BDTX is a scientific stage firm it doesn’t have any authorized product in its portfolio and therefore doesn’t generate product gross sales. Nonetheless, the corporate earns license revenues from its collaboration settlement.
In such a situation, buyers will primarily give attention to pipeline updates.
BDTX is growing MasterKey therapies that focus on households of oncogenic mutations in sufferers with most cancers.
Silevertinib is a brain-penetrant, fourth-generation epidermal development issue receptor (EGFR) MasterKey inhibitor concentrating on EGFR-mutant (EGFRm) non-small cell lung most cancers (NSCLC) and glioblastoma (GBM).
The candidate was proven to be properly tolerated and achieved sturdy scientific responses in a part I examine in sufferers with recurrent EGFRm NSCLC whose tumors expressed a spread of mutation subtypes, together with the acquired C797S resistance mutation and a broad spectrum of non-classical mutations.
BDTX is at the moment evaluating silevertinib in a part II examine in sufferers with EGFRm NSCLC in each the recurrent setting (cohorts 1 and a pair of) and the frontline setting (cohort 3).
In July 2025, enrollment in frontline sufferers harboring non-classical EGFR mutations (cohort 3, n=43) was accomplished. BDTX plans to reveal goal response charges and preliminary length of response information from all sufferers with frontline NSCLC and non-classical EGFR mutations within the fourth quarter of 2025.
The developmental plan for silevertinib contains FDA suggestions on a possible registrational path in frontline EGFRm NSCLC within the first half of 2026, when progression-free survival information from the continuing part II examine can be found.
BDTX can also be exploring potential collaborators to advance silevertinib additional NSCLC and glioblastoma. Updates on the identical will likely be anticipated.
R&D bills have possible declined within the third quarter because of workforce efficiencies and outlicensing of BDTX-4933 to extend give attention to the event of silevertinib.
Common and Administrative bills have additionally possible declined as a result of restructuring introduced in October 2024.
BDTX’s Worth Efficiency and Valuation
12 months to this point, BDTX shares have skyrocketed 78.5% in contrast with the trade’s development of 10.5% up to now this 12 months. The inventory has additionally outperformed the sector and the S&P 500 Index on this time-frame.
BDTX Outperforms Business, Sector and Index
Picture Supply: Zacks Funding Analysis
From a valuation standpoint, BDTX is cheap. Going by the worth/e-book ratio, BDTX’s shares at the moment commerce at 1.64x e-book worth, decrease than its imply of 1.31x and the biotech trade’s 3.45x.
Picture Supply: Zacks Funding Analysis
Funding Thesis for BDTX
The oncology market is likely one of the most profitable areas within the pharma sector. Whereas competitors is stiff within the NSCLC house from bigwigs like Johnson & Johnson JNJ and AstraZeneca AZN, silevertinib has proven promise.
Importantly, per BDTX, silevertinib has the potential to deal with each newly recognized sufferers with EGFRm NSCLC and people with recurrent illness, because of its skill to focus on greater than 50 classical and non-classical oncogenic driver mutations with larger efficiency than different EGFR tyrosine kinase inhibitors (TKIs). Moreover, it targets the C797S resistance mutation, which may emerge after remedy with AZN’s Tagrisso (osimertinib), a number one NSCLC drug.
Black Diamond ended the second quarter of 2025 with roughly $142.8 million in money and money equivalents. BDTX believes the money stability is adequate to fund its anticipated working bills and capital expenditure necessities into the fourth quarter of 2027.
BDTX entered into a worldwide licensing settlement with Servier Prescribed drugs in March 2025 for its second clinical-stage asset, BDTX-4933, a possible best-in-class focused remedy for RAF/RAS-mutant strong tumors. The corporate acquired an upfront fee of $70.0 million.
Following the outlicensing of its different pipeline candidate, BDTX-4933, to Servier Prescribed drugs, BDTX is solely centered on the event of silevertinib.
Keep Invested in BDTX Inventory
Whereas BDTX’s efforts to develop silevertinib are spectacular, the corporate has just one pipeline candidate as of now. Any setback within the growth of silevertinib will likely be detrimental to buyers’ pursuits.
No matter how the third-quarter outcomes play out, we suggest potential buyers to attend and watch how BDTX advances silevertinib earlier than turning optimistic.
For buyers already proudly owning the inventory, staying invested at present ranges can be a prudent transfer as any optimistic information readout on silevertinib will positively influence the share worth.
You’ll be able to see the whole listing of at present’s Zacks #1 Rank shares right here.
AstraZeneca PLC (AZN) : Free Inventory Evaluation Report
Johnson & Johnson (JNJ) : Free Inventory Evaluation Report
Black Diamond Therapeutics, Inc. (BDTX) : Free Inventory Evaluation Report
This text initially printed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
